Background: Transcatheter aortic valve replacement (TAVR) is a recent and an effective treatment option for high- or extreme-surgical-risk patients with symptomatic severe aortic stenosis. However, pure severe native aortic valve regurgitation (NAVR) without aortic stenosis remains a contraindication to TAVR. The aim of our systemic review analysis was to evaluate TAVR in patients with pure NAVR. Methods: We searched the published articles in the PubMed and Web of Science databases (2002–2017) using the Boolean operators for studies of NAVR patients undergoing TAVR. Reference lists of all returned articles were searched recursively for other relevant citations. Pooled estimates were calculated using a random-effects meta-analysis. Results: Finally, a total of 10 studies were included in this analysis. The CoreValve was more frequently used with a lower rate of device success and a higher rate of residual aortic regurgitation. The new-generation transcatheter heart valves (THVs) performed a significantly higher rate with less residual aortic regurgitation and a success rate close to 100%. The 30-day all-cause mortality rates ranged from 0 to 30% with an estimate summary rate of 9% (95% CI: 5–15%; I2 = 33%). Cerebrovascular events, major or life-threatening bleeding, major vascular complications, acute kidney disease, and new permanent pacemaker implantation occurred similarly in both the new- and old-generation THV devices. Conclusions: Aortic regurgitation remains a challenging pathology for TAVR. TAVR is a feasible and reasonable option for carefully selected patients with pure aortic regurgitation.

1.
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106: 3006–3008.
2.
Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, Barbanti M, Latib A, Schaefer U, Rodes-Cabau J, Treede H, Piazza N, Hildick-Smith D, Himbert D, Walther T, Hengstenberg C, Nissen H, Bekeredjian R, Presbitero P, Ferrari E, Segev A, de Weger A, Windecker S, Moat NE, Napodano M, Wilbring M, Cerillo AG, Brecker S, Tchetche D, Lefevre T, De Marco F, Fiorina C, Petronio AS, Teles RC, Testa L, Laborde JC, Leon MB, Kornowski R; Valve-in-Valve International Data Registry I: Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014; 312: 162–170.
3.
Mylotte D, Lefevre T, Sondergaard L, Watanabe Y, Modine T, Dvir D, Bosmans J, Tche-tche D, Kornowski R, Sinning JM, Theriault-Lauzier P, O’Sullivan CJ, Barbanti M, Debry N, Buithieu J, Codner P, Dorfmeister M, Martucci G, Nickenig G, Wenaweser P, Tamburino C, Grube E, Webb JG, Windecker S, Lange R, Piazza N: Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 2014; 64: 2330–2339.
4.
Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Sondergaard L: Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 2015; 65: 2184–2194.
5.
Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quinones M; EAE/ASE: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009; 10: 1–25.
6.
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M: ESC Committee for Practice Guidelines (CPG); , Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS): Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012; 42:S1–S44.
7.
Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Mollmann H, Dumonteil N, Modine T, Bosmans J, Petronio AS, Moat N, Linke A, Moris C, Champagnac D, Parma R, Ochala A, Medvedofsky D, Patterson T, Woitek F, Jahangiri M, Laborde JC, Brecker SJ: Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol 2013; 61: 1577–1584.
8.
Rossi M, Barbaro C, Pagnotta P, Lucarelli C, Mennuni M, Presbitero P: Transcatheter aortic valve implantation in patients with pure severe native aortic regurgitation: results after 3 year of follow-up (abstract). J Am Coll Cardiol 2014; 64:B220–B221.
9.
Schlingloff F, Schafer U, Frerker C, Schmoeckel M, Bader R: Transcatheter aortic valve implantation of a second-generation valve for pure aortic regurgitation: procedural outcome, haemodynamic data and follow-up. Interact Cardiovasc Thorac Surg 2014; 19: 388–393.
10.
Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, Hofmann S, Arnold M, Kallenbach K, Conradi L, Schlingloff F, Wilbring M, Schafer U, Diemert P, Treede H: Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv 2014; 7: 1168–1174.
11.
Testa L, Latib A, Rossi ML, De Marco F, De Carlo M, Fiorina C, Oreglia J, Petronio AS, Ettori F, De Servi S, Klugmann S, Ussia GP, Tamburino C, Panisi P, Brambilla N, Colombo A, Presbitero P, Bedogni F: CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention 2014; 10: 739–745.
12.
Wendt D, Kahlert P, Pasa S, El-Chilali K, Al-Rashid F, Tsagakis K, Dohle DS, Erbel R, Jakob H, Thielmann M: Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits. JACC Cardiovasc Interv 2014; 7: 1159–1167.
13.
Munoz-Garcia E, Munoz-Garcia M, Munoz-Garcia A, Dominguez-Franco A, Jimenez-Navarro M, Alonso-Briales J: Safety of transcatheter aortic valve implantation in patients with pure native aortic valve regurgitation (abstract). Eur Heart J 2015; 36: 793.
14.
Schofer J, Nietlispach F, Bijuklic K, Colombo A, Gatto F, De Marco F, Mangieri A, Hansen L, Bruschi G, Ruparelia N, Riess FC, Maisano F, Latib A: Transfemoral implantation of a fully repositionable and retrievable transcatheter valve for noncalcified pure aortic regurgitation. JACC Cardiovasc Interv 2015; 8: 1842–1849.
15.
Zhu D, Wei L, Cheung A, Guo Y, Chen Y, Zhu L, Liu H, Yang Y, Zhang J, Wang C: Treatment of pure aortic regurgitation using a second-generation transcatheter aortic valve implantation system. J Am Coll Cardiol 2016; 67: 2803–2805.
16.
Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, Latib A, Petronio AS, Rodes-Cabau J, Taramasso M, Spaziano M, Bosmans J, Biasco L, Mylotte D, Savontaus M, Gheeraert P, Chan J, Jorgensen TH, Sievert H, Mocetti M, Lefevre T, Maisano F, Mangieri A, Hildick-Smith D, Kornowski R, Makkar R, Bleiziffer S, Sondergaard L, De Backer O: Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study. JACC Cardiovasc Interv 2017; 10: 1048–1056.
17.
D’Ancona G, Pasic M, Buz S, Drews T, Dreysse S, Hetzer R, Unbehaun A: TAVI for pure aortic valve insufficiency in a patient with a left ventricular assist device. Ann Thorac Surg 2012; 93:e89–e91.
18.
Barbanti M, Ye J, Pasupati S, El-Gamel A, Webb JG: The Helio transcatheter aortic dock for patients with aortic regurgitation. EuroIntervention 2013; 9(suppl):S91–S94.
19.
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators: Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187–2198.
20.
Foerst J: Percutaneous repair of left ventricular wire perforation complicating transcatheter aortic valve replacement for aortic regurgitation. JACC Cardiovasc Interv 2016; 9: 1410–1411.
21.
Wohrle J, Rodewald C, Rottbauer W: Transfemoral aortic valve implantation in pure native aortic valve insufficiency using the repositionable and retrievable lotus valve. Catheter Cardiovasc Interv 2016; 87: 993–995.
22.
Saraf S, Khawaja MZ, Hilling-Smith R, Doo-ley M, Cockburn J, Trivedi U, Hildick-Smith D: Use of the Lotus transcatheter valve to treat severe native aortic regurgitation. Ann Thorac Surg 2017; 103:e305–e307.
23.
Lauten A, Ferrari M, Petri A, Ensminger SM, Gummert JF, Boudjemline Y, Schubert H, Schumm J, Hekmat K, Schlosser M, Figulla HR: Experimental evaluation of the JenaClip transcatheter aortic valve. Catheter Cardiovasc Interv 2009; 74: 514–519.
24.
Sundermann SH, Grunenfelder J, Corti R, Rastan AJ, Linke A, Lange R, Falk V, Bleiziffer S: Feasibility of the Engager aortic transcatheter valve system using a flexible over-the-wire design. Eur J Cardiothorac Surg 2012; 42:e48–e52.
25.
Kiefer P, Seeburger J, Mohr FW, Holzhey DM: Transcatheter aortic valve replacement for isolated aortic valve insufficiency: experience with the Engager valve. J Thorac Cardiovasc Surg 2014; 147:e37–e38.
26.
Shang EK, Nathan DP, Sprinkle SR, Vigmostad SC, Fairman RM, Bavaria JE, Gorman RC, Gorman JH 3rd, Chandran KB, Jackson BM: Peak wall stress predicts expansion rate in descending thoracic aortic aneurysms. Ann Thorac Surg 2013; 95: 593–598.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.